The results of imatinib therapy for patients with primary eosinophilic disorders-Reference-Cited by-同舟云学术

The results of imatinib therapy for patients with primary eosinophilic disorders

Published:2006-06 Issue:6 Volume:76 Page:535-536
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Helbig Grzegorz,Stella-Holowiecka Beata,Grosicki Sebastian,Bober Grazyna,Krawczyk Magorzata,Wojnar Jerzy,Reiter Andreas,Hochhaus Andreas,Holowiecki Jerzy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2006.00652.x/fullpdf

Reference7 articles.

1. Modern Diagnosis and Treatment of Primary Eosinophilia

2. THE HYPEREOSINOPHILIC SYNDROME

3. A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

4. Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myelomonocytic Leukemia: Hematopathology Perspective;Journal of Immunotherapy and Precision Oncology;2021-06-18

2. Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis — Chronic Myelomonocytic Leukemia and Beyond;Current Hematologic Malignancy Reports;2021-05-04

3. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms;Surgical Pathology Clinics;2019-09

4. Recent Updates on Chronic Myelomonocytic Leukemia;Current Hematologic Malignancy Reports;2018-10-11

5. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia;Journal of Hematology & Oncology;2014-03-27